OGN Stock Recent News
OGN LATEST HEADLINES
JERSEY CITY, N.J.--(BUSINESS WIRE)--Organon enters agreement to acquire Dermavant including innovative VTAMA (tapinarof) cream, 1%, a novel, non-steroidal topical dermatologic therapy.
Organon (OGN) concluded the recent trading session at $20.47, signifying a +0.89% move from its prior day's close.
JP Morgan notes that while there's a resurgence of interest and excitement in new product launches within the specialty group, including branded and complex generics/biosimilars, investors should be discerning about these opportunities.
Organon (OGN) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.
Although the revenue and EPS for Organon (OGN) give a sense of how its business performed in the quarter ended June 2024, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.
Organon (OGN) came out with quarterly earnings of $1.12 per share, beating the Zacks Consensus Estimate of $1.06 per share. This compares to earnings of $1.31 per share a year ago.
As the 2024 US presidential election approaches, speculation about Kamala Harris potentially stepping into the Oval Office remains strong. Despite Donald Trump's assertion that Harris would be an easier opponent than Joe Biden, recent developments suggest Harris's presidency is a viable scenario.
Continued solid uptake of Organon's (OGN) products is expected to have driven second-quarter revenues.
Besides Wall Street's top -and-bottom-line estimates for Organon (OGN), review projections for some of its key metrics to gain a deeper understanding of how the company might have fared during the quarter ended June 2024.
In the latest trading session, Organon (OGN) closed at $21.86, marking a -1.84% move from the previous day.